Hepcidin and its relationship with inflammation in old and older patients with anemia of chronic disease associated with CHF

Background. Reported levels of hepcidin, the major regulator of systemic iron homeostasis in CHF patients, are controversial. Relationship of hepcidin with inflammation markers, which are typically increased in CHF, is understudied; this issue is practically unstudied in old and older CHF patients. Aim. To study the role of hepcidin in development of anemia of chronic disease (ACD) and the association of hepcidin with inflammation in old and older CHF patients. Materials and methods. Ninety old and older patients with IHD were evaluated. 35 of these patients had CHF and ACD and 35 patients had CHF without ACD. The control group (CG) consisted of 20 IHD patients without CHF and ACD. Serum concentration of hepcidin was measured using ELISA by the competitive binding principle. Results. Patients with severe, congestive FC IV CHF prevailed among CHF patients with ACD, and their CHF was characterized with longer duration, more frequent hospitalizations, and lower compliance with the treatment. Significantly higher mean levels of hepcidin, C-reactive protein (CRP), erythrocyte sedimentation rate, and insignificantly higher levels of ferritin were observed in CHF patients with than without ACD. The high hepcidin, indexes of inflammation tests, and a significant positive correlation of hepcidin with hemoglobin levels suggested inflammation as a cause for the increased hepcidin, which induced anemia in old and older CHF patients with ACD.

хроническая сердечная недостаточность, анемия хронических заболеваний, гепсидин, пожилой и старческий возраст, chronic heart failure, anemia of chronic disease, hepcidin, old and older age

1. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG et al. Etiology of anemia in patients with advanced heart failure. Journal of the American College of Cardiology. 2006;48 (12):2485-9. DOI:10.1016/j. jacc. 2006.08.034

2. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12065 patients with new-onset heart failure. Circulation. 2003;107 (2):223-5

3. Kemna EHJM, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica. 2008;93 (l):90-7. DOI:10.3324/haematol. 11705

4. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P et al. A new mouse liver-specific gene, encoding a protein hmologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. Journal of Biological Chemistry. 2001;276 (ll):7811-9. DOI:10.1074/jbc. M008923200

5. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. Journal of Biological Chemistry. 2001;276 (11):7806-10. DOI:10.1074/jbc. M008922200

6. Finberg KE. Regulation of systemic iron homeostasis. Current Opinion in Hematology. 2013;20 (3):208-14. DOI:10.1097/MOH. 0b013e32835f5a47

7. Nairz M, Theurl I, Wolf D, Weiss G. Iron deficiency or anemia of inflammation? Differential diagnosis and mechanisms of anemia of inflammation. Wiener Medizinische Wochenschrift. 2016;166 (13-14):411-23. DOI: 10.1007/s 10354-016-0505-7

8. Arezes J, Nemeth E. Hepcidin and iron disorders: new biology and clinical approaches. International Journal of Laboratory Hematology. 2015;37:92-8. DOI:10.1111 /ijlh. 12358

9. Weiss G, Goodnough LT. Anemia of chronic disease. New England Journal ofMedicine. 2005;352 (10):1011-23. DOI:10.1056/NEJM-ra041809

10. Зубрихина Г. Н., Блиндарь В. Н., Матвеева И. И. Дифференциальная диагностика анемического синдрома при истинном железодефицитном состоянии и функциональном дефиците железа у больных с хроническими заболеваниями (злокачественными новообразованиями). Терапевтический архив. 2016;88 (4):61-7

11. Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS, et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management: CAPPELLINI et al. American Journal of Hematology. 2017;92 (10):1068-78. DOI:10.1002/ajh. 24820

12. Divakaran V, Mehta S, Yao D, Hassan S, Simpson S, Wiegerinck E et al. Hepcidin in anemia of chronic heart failure. American Journal of Hematology. 2011;86 (1):107-9. DOI:10.1002/ajh. 21902

13. Pozzo J, Fournier P, Delmas C, Vervueren P-L, Roncalli J, Elbaz M et al. Absolute iron deficiency without anaemia in patients with chronic systolic heart failure is associated with poorer functional capacity. Archives of Cardiovascular Diseases. 2017;110 (2):99-105. DOI:10.1016/j. acvd. 2016.06.003

14. Vela D. Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology. Laboratory Investigation [Internet]. 2017 [cited 2018]; DOI:10.1038/labinvest. 2017.111

15. Щукин Ю. В., Березин И. И., Медведева Е. А., Дьячков В. А., Слатова Л. Н. О значении галектина-3 как маркера и медиатора эндогенного воспаления и окислительно-нитрозилирующего стресса у больных ХСН. Российский Кардиологический Журнал. 2013; (2 (100)): 45-9

16. Костенко В. А., Ситникова М. Ю., Скородумова Е. А., Скородумова Е. Г., Федоров А. Н. Прогностическое значение коэффициента анизотропии эритроцитов у пациентов, госпитализированных по поводу острой декомпенсированной ХСН. Российский кардиологический журнал. 2017; (12):26-30

17. Rajendiran KS, Ananthanarayanan RH, Satheesh S, Rajappa M. Elevated levels of serum sialic acid and high-sensitivity C-reactive protein: markers of systemic inflammation in patients with chronic heart failure. Br J Biomed Sci. 2014;71 (1):29-32

18. Singh DK, Winocour P, Summerhayes B, Viljoen A, Sivakumar G, Farrington K. Are low erythropoietin and 1,25-dihydroxyvita-min D levels indicative of tubulo-interstitial dysfunction in diabetes without persistent microalbuminuria? Diabetes Research and Clinical Practice. 2009;85 (3):258-64. DOI:10.1016/j. diabres. 2009.06.022

19. Хантакова Е. А. Анемический синдром у больных СД 1 типа при диабетической нефропатии. Сибирский Медицинский Журнал (Иркутск). 2013;119 (4):51-4